

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-3184

STEVEN L. HIGHLANDER
PARTNER


INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

May 29, 2001

FILE: IOWA:026US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 29, 2001 Date	 Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/642,744 "ALPHA HELICAL PEPTIDES WITH BROAD SPECTRUM
ANTIMICROBIAL ACTIVITY THAT ARE INSENSITIVE TO SALT" – Brian F. Tack et
al. (Client Ref. URIF N9-28/2001-135-1)

Commissioner:


Enclosed for filing in the above-referenced patent application is:

1. An Amendment and Response to Official Communication Dated March 28, 2001;
2. A Substitute Sequence Listing;
3. Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g);
4. Substitute computer-readable form (CRF) copy of the Sequence Listing, and a separate paper copy;
5. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; and
6. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Commissioner for Patents
May 29, 2001
Page 2

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10008937/IOWA:026US/SLH.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/cpj
Encl.:

Box Set
0360



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/642,744	08/18/2000	Brian Tack	IOWA:026US

Docketing Purposes
600 Congress Avenue
Suite 1900
Austin, TX 78701

FORMALITIES LETTER




Date Mailed: 03/28/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - o A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY